TransEnterix (TRXC) Announces Brett Farabaugh to Interim CFO, Following Retirement of Joe Slattery

TransEnterix, Inc. (NYSE: TRXC) today announced that Brett Farabaugh has joined as interim Chief Financial Officer, effective January 2, 2020, replacing Joe Slattery who retired December 31, 2019, as previously announced.

“We are very excited to have Brett join the TransEnterix team. He brings a wealth of experience providing financial leadership to high growth healthcare and technology companies,” said Anthony Fernando, TransEnterix President and Chief Executive Officer. “I believe Brett’s in depth knowledge of the medical device industry and his background of successfully guiding innovative companies will be very valuable during this critical period as we focus on taking the actions needed to implement changes in our commercial strategy that I believe will drive shareholder value.”

Mr. Farabaugh has served as CFO of Tryton Medical, Inc., a developer of coronary stents based in Durham, North Carolina since August 2008, and as CEO of Tryton Medical since August 2019. Prior to Tryton Medical, Mr. Farabaugh served as CFO of Strikeiron, Inc., a high-growth information technology company, from 2006-2008, as Vice President of Finance for Icoria, Inc. (formerly Paradigm Genetics, Inc.), a biotechnology company, from 2004-2006. Mr. Farabaugh also held various roles at Nuada Pharmaceuticals and PricewaterhouseCoopers LLP. Mr. Farabaugh holds a B.S. in Commerce with a concentration in Accounting from the University of Virginia and is a licenced CPA.

You May Also Be Interested In

• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• Atlassian (TEAM) Announces Resignation of Co-CEO Scott Farquhar
• Akanda Corp (AKAN) Appoints Christopher Cooper to its Board